Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:MDXHNASDAQ:PSNLNASDAQ:SERANASDAQ:XGN On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeMDXHMDxHealth$1.76+1.7%$1.60$1.35▼$3.50$83.23M1.2983,114 shs29,337 shsPSNLPersonalis$3.84+0.3%$3.77$1.14▼$7.20$339.10M1.89969,147 shs366,554 shsSERASera Prognostics$3.16-5.7%$3.79$2.99▼$12.36$119.02M0.96130,806 shs54,409 shsXGNExagen$6.21+6.2%$3.93$1.32▼$6.23$111.15M1.4688,627 shs137,223 shs The Best Nuclear Energy Stocks to BuyNuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceMDXHMDxHealth+0.58%+8.12%+10.19%-13.50%-30.52%PSNLPersonalis+4.08%+20.06%+6.39%-37.42%+194.62%SERASera Prognostics-2.05%-1.47%-17.28%-48.85%-66.63%XGNExagen+2.27%+30.29%+51.55%+46.25%+327.01%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationMDXHMDxHealth2.7952 of 5 stars3.55.00.00.00.00.01.3PSNLPersonalis3.9237 of 5 stars3.51.00.04.23.32.50.6SERASera Prognostics0.5149 of 5 stars0.02.00.00.02.12.50.0XGNExagen3.866 of 5 stars2.53.00.04.52.73.30.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceMDXHMDxHealth 3.00Buy$6.50269.32% UpsidePSNLPersonalis 3.00Buy$7.80103.13% UpsideSERASera Prognostics 3.00BuyN/AN/AXGNExagen 3.00Buy$7.5020.77% UpsideCurrent Analyst Ratings BreakdownLatest MDXH, PSNL, SERA, and XGN Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails4/10/2025PSNLPersonalisNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$7.00 ➝ $7.003/17/2025PSNLPersonalisCraig HallumSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$8.003/12/2025XGNExagenWilliam BlairSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform2/28/2025PSNLPersonalisHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$8.00 ➝ $8.002/28/2025PSNLPersonalisNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$7.25 ➝ $7.001/27/2025PSNLPersonalisHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$11.00 ➝ $8.00(Data available from 4/25/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookMDXHMDxHealth$90.05M0.92N/AN/A$4.62 per share0.38PSNLPersonalis$84.61M4.01N/AN/A$2.64 per share1.45SERASera Prognostics$77K1,545.69N/AN/A$2.21 per share1.43XGNExagen$55.64M2.00N/AN/A$1.33 per share4.67Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateMDXHMDxHealth-$43.10M-$1.27N/AN/AN/A-49.52%-1,077.84%-28.82%5/7/2025 (Estimated)PSNLPersonalis-$108.30M-$1.37N/AN/AN/A-104.52%-66.07%-41.34%5/6/2025 (Estimated)SERASera Prognostics-$36.24M-$0.99N/AN/AN/AN/A-51.73%-36.94%5/14/2025 (Estimated)XGNExagen-$23.69M-$0.83N/AN/AN/A-30.36%-92.58%-33.74%5/12/2025 (Estimated)Latest MDXH, PSNL, SERA, and XGN EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/14/2025Q1 2025SERASera Prognostics-$0.24N/AN/AN/A$0.06 millionN/A5/12/2025Q1 2025XGNExagen-$0.20N/AN/AN/A$14.55 millionN/A5/7/2025Q1 2025MDXHMDxHealth-$0.13N/AN/AN/A$22.62 millionN/A5/6/2025Q1 2025PSNLPersonalis-$0.23N/AN/AN/A$17.41 millionN/A3/19/2025Q4 2024SERASera Prognostics-$0.23-$0.25-$0.02-$0.25$0.01 million$0.02 million2/27/2025Q4 2024PSNLPersonalis-$0.32-$0.23+$0.09-$0.23$15.48 million$16.80 million2/26/2025Q4 2024MDXHMDxHealth-$0.21-$0.14+$0.07-$0.14$22.67 million$24.74 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthMDXHMDxHealthN/AN/AN/AN/AN/APSNLPersonalisN/AN/AN/AN/AN/ASERASera PrognosticsN/AN/AN/AN/AN/AXGNExagenN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioMDXHMDxHealth3.141.541.45PSNLPersonalisN/A4.684.44SERASera PrognosticsN/A2.112.11XGNExagen1.544.054.05Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipMDXHMDxHealthN/APSNLPersonalis61.91%SERASera Prognostics54.64%XGNExagen75.25%Insider OwnershipCompanyInsider OwnershipMDXHMDxHealth1.70%PSNLPersonalis3.80%SERASera Prognostics15.80%XGNExagen26.10%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableMDXHMDxHealth30047.29 million46.48 millionNot OptionablePSNLPersonalis40088.31 million67.75 millionOptionableSERASera Prognostics12037.66 million28.44 millionOptionableXGNExagen22017.90 million13.03 millionOptionableMDXH, PSNL, SERA, and XGN HeadlinesRecent News About These CompaniesInstitutional investors control 30% of Exagen Inc. (NASDAQ:XGN) and were rewarded last week after stock increased 30%April 25 at 9:55 AM | finance.yahoo.comExagen Inc. to Announce First Quarter 2025 Financial Results on May 5, 2025April 21, 2025 | globenewswire.comExagen Inc. (NASDAQ:XGN) Shares Sold by Wasatch Advisors LPApril 20, 2025 | marketbeat.comExagen Inc. (NASDAQ:XGN) Short Interest UpdateApril 16, 2025 | marketbeat.comShort Interest in Exagen Inc. (NASDAQ:XGN) Drops By 23.5%March 31, 2025 | marketbeat.comExagen Inc. (NASDAQ:XGN) Just Reported Annual Earnings: Have Analysts Changed Their Mind On The Stock?March 14, 2025 | finance.yahoo.comExagen Full Year 2024 Earnings: EPS Beats ExpectationsMarch 12, 2025 | uk.finance.yahoo.comExagen Inc. (NASDAQ:XGN) Q4 2024 Earnings Call TranscriptMarch 12, 2025 | msn.comExagen (XGN) Gets a Buy from Canaccord GenuityMarch 12, 2025 | markets.businessinsider.comExagen Inc. Reports Record Revenue and Positive OutlookMarch 12, 2025 | tipranks.comExagen reports Q4 EPS (20c), consensus (24c)March 12, 2025 | markets.businessinsider.comExagen Inc. Reports Record 2024 Financial ResultsMarch 12, 2025 | tipranks.comExagen Inc. (XGN) Q4 2024 Earnings Call TranscriptMarch 11, 2025 | seekingalpha.comExagen Inc. Reports Strong Fourth Quarter and Full-Year 2024 Results and Business HighlightsMarch 11, 2025 | globenewswire.comInvestors in Exagen (NASDAQ:XGN) have unfortunately lost 84% over the last five yearsMarch 2, 2025 | finance.yahoo.comExagen Inc. to Announce Fourth Quarter and Full-Year 2024 Financial Results on March 11, 2025February 25, 2025 | globenewswire.comExagen granted planning consent for 34MWp solar and 75MW BESS projectFebruary 13, 2025 | solarpowerportal.co.ukStrength Seen in Exagen (XGN): Can Its 29.4% Jump Turn into More Strength?February 5, 2025 | zacks.comExagen Inc. to Participate in Upcoming Investor ConferencesFebruary 4, 2025 | globenewswire.comRevealed Tomorrow: The Stocks Poised for Big Gains in FebruaryFebruary 2, 2025 | msn.comExagen Gains 28%, Insider Trades Reap BenefitJanuary 20, 2025 | finance.yahoo.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeMDXH, PSNL, SERA, and XGN Company DescriptionsMDxHealth NASDAQ:MDXH$1.76 +0.03 (+1.73%) As of 04:00 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.MDxHealth SA, a commercial-stage precision diagnostics company, provides urologic solutions in the United States, Europe, and internationally. Its testing solutions includes Select mdx, a non-invasive urine test for prostate cancer that measures the expression of two mRNA cancer-related biomarkers; Confirm mdx for prostate cancer tissue test that validates epigenetic test that guides the detection of occult prostate cancer on a patient's previously biopsied negative tissue; and Resolved mdx for urinary tract infection that identifies personalized effective antibiotic options against the patient's infection. The company offers genomic prostate score which provides personalized genomic insights to both physicians and patients navigating the complexities of prostate cancer diagnosis and treatment. It sells its products through urology sales force, consisting of direct sales representatives, strategic account managers, and regional sales managers. The company was formerly known as OncoMethylome Sciences SA and changed its name to MDxHealth SA in October 2010. MDxHealth SA was incorporated in 2003 and is headquartered in Herstal, Belgium.Personalis NASDAQ:PSNL$3.84 +0.01 (+0.26%) Closing price 04:00 PM EasternExtended Trading$3.84 0.00 (-0.13%) As of 04:05 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Personalis, Inc. develops and markets advanced cancer genomic tests and analytics primarily in the United States, Europe, and the Asia-Pacific. Its tests and analytics are used by pharmaceutical companies for translational research, biomarker discovery, and development of personalized cancer therapies, as well as advanced tests are used by physicians to detect cancer recurrence, monitor cancer evolution, and uncover insights for therapy selection. The company offers NeXT Personal, a tumor-informed liquid biopsy test for detection of minimal residual disease (MRD) and recurrence in cancer; and ImmunoID NeXT, a tissue-based test that combines whole exome (DNA) and whole transcriptome (RNA) sequencing data with advanced analytics to provide a multi-dimensional view of the tumor and the tumor microenvironment from a single sample. It also provides NeXT Personal Dx, a tumor-informed liquid biopsy test for detection of MRD and recurrence in cancer; and NeXT Dx, a comprehensive tumor profiling test that unlocks the entire exome (DNA) and transcriptome (RNA) with matched tumor-normal analysis. In addition, the company performs whole exome sequencing (WES) of cancer tissue and matched blood samples for diagnostic companies as an input to their products; and whole genome sequencing (WGS) on human samples for research projects, such as population sequencing initiatives, as well as offers sequencing and data analysis services to support population sequencing initiatives. Its customers include pharmaceutical companies, biopharmaceutical companies, diagnostics companies, universities, non-profits, government entities, and patients. The company was incorporated in 2011 and is headquartered in Fremont, California.Sera Prognostics NASDAQ:SERA$3.16 -0.19 (-5.67%) Closing price 04:00 PM EasternExtended Trading$3.18 +0.01 (+0.47%) As of 06:56 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Sera Prognostics, Inc., a women's health diagnostic company, discovers, develops, and commercializes biomarker tests for improving pregnancy outcomes in the United States. The company develops PreTRM test, a blood-based biomarker test to predict the risk of spontaneous preterm birth in singleton pregnancies. It is also developing a portfolio of product candidates for various pregnancy-related conditions, including preterm birth, preeclampsia, molecular time-to-birth, predictive analytics, gestational diabetes mellitus, fetal growth restriction, stillbirth, and postpartum depression. The company was incorporated in 2008 and is headquartered in Salt Lake City, Utah.Exagen NASDAQ:XGN$6.21 +0.36 (+6.15%) Closing price 04:00 PM EasternExtended Trading$6.20 -0.01 (-0.16%) As of 06:48 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Exagen Inc. develops and commercializes various testing products under the AVISE brand in the United States. The company enables healthcare providers to care for patients through the diagnosis, prognosis, and monitoring of autoimmune and autoimmune-related diseases, including systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA). Its lead testing product is AVISE CTD that enables differential diagnosis for patients presenting with symptoms indicative of various connective tissue diseases (CTDs) and other related diseases with overlapping symptoms. The company offers AVISE Lupus that measures activation of the complement system by quantifying the level of B-cell C4d and erythrocyte bound C4d in the patient's blood; and AVISE APS, which consists of a panel of autoantibody tests that aids in the diagnosis and management of APS. In addition, it provides AVISE Vasculitis AAV, which utilizes a testing panel of individual analytes to provide physicians with results in the assessment and monitoring of anti-neutrophil cytoplasmic antibody associated vasculitis; AVISE SLE Prognostic, a panel of autoantibodies for assessing the potential for complications affecting the kidney, brain, and cardiovascular system; and AVISE Anti-CarP test, which identifies RA patients with severe disease. Further, the company offers AVISE SLE Monitor, a biomarker blood test; AVISE MTX, a patented and validated blood test; and AVISE HCQ, a blood test to monitor levels of hydroxychloroquine. It has a research collaboration and license agreement with Allegheny Health Network (AHN) Research Institute to develop novel patented biomarkers. The company was formerly known as Exagen Diagnostics, Inc. and changed its name to Exagen Inc. in January 2019. Exagen Inc. was incorporated in 2002 and is headquartered in Vista, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas If You Wanted To Buy AbbVie and Didn’t, There’s Still Time To Buy 3 Stocks To Watch For When Tariffs Subside 3 Boring Stocks Outperforming the Market This Year Short Sellers Gave Up on These 3 Names Recently Market Anticipation Builds: Joby Stock Climbs Ahead of Earnings Is Intuitive Surgical a Buy After Volatile Reaction to Earnings? Now Is the Time to Buy ServiceNow—The Rebound Is Real Archer Aviation Gets Analyst Target Upgrade: Time to Load Up? Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
